Zhenyi Medical Shines at China Heart Congress 2025 with Innovative Cardiovascular Solutions

It is worth noting that, on the afternoon of the opening day,Pre-Market Clinical Trial Regulations, Design, and Evaluation Forum for Medical DevicesSparking High Attention. The forum precisely targets the core pain points of current medical device innovation and transformation—how to scientifically and efficiently complete pre-market clinical trials to ensure product safety and efficacy? The venue was fully packed, with representatives from the National Cardiovascular Center, top clinical research centers of leading hospitals in China, and enterprises engaging in in-depth discussions on regulatory compliance, trial design optimization, data statistical analysis, and clinical value evaluation. The atmosphere was enthusiastic.

As a "pioneer" in the innovation of cardiovascular interventional medical devices in China, Trulive was invited to deeply participate in this forum.Company representatives, together with industry peers, shared practical experiences based on their product characteristics and sparked numerous constructive ideas through discussions with top experts, becoming one of the highlights of the forum. Trulive's impressive performance is rooted in the company's continuous dedication to the field of cardiovascular disease treatment. Currently, the company has developed an innovative product portfolio addressing cardiovascular diseases with extremely high mortality and disability rates, such as valve, peripheral, and coronary conditions, where the domestic market remains underserved. Among these, three core products have been successfully launched and widely applied in clinical practice.

Among them, the NeoNova® Transcatheter Mitral Valve Edge-to-Edge Repair System, independently developed by Trulive, has been rapidly applied in clinical settings across multiple provinces and cities in China since its launch earlier this year, thanks to its product performance and technical advantages, earning high praise from clinical experts. At the forum,Mr. Jingyu Lin, Head of Clinical Affairs at TruliveTaking this product as an example, experts conducted in-depth discussions on topics such as "Key Statistical Design Points for Clinical Trials of High-End Interventional Devices," "The Impact of Operator Training Systems on Clinical Outcomes," and "Real-World Data Feedback Mechanisms During the Commercialization Phase." The attending experts, combining clinical practice, provided multidimensional suggestions ranging from indication expansion, procedure optimization, to long-term patient management, offering valuable references for subsequent product iteration and clinical promotion by the company.

"Trulive Medtech always takes 'saving hundreds of millions of patients’ lives' as its original intention, focusing on the field of cardiovascular diseases with high mortality and disability rates that remain a gap in the Chinese market. It strives to use independent innovation to break the monopoly of imported products and provide global patients with safer, more accessible, and more efficient solutions made in China." Lin Jingyu stated that this participation is not only about showcasing achievements but also about exploring with top industry forces how innovative products can benefit patients faster and better.

From the laboratory to the operating room, from technological breakthroughs to clinical validation, every step taken by the company is closely aligned with clinical needs, guided by the principle of "solving real problems." Trulive is contributing more Chinese solutions for cardiovascular disease patients worldwide. During this year's CHC, the Trulive product booth attracted a steady stream of visitors. Clinical doctors and distributors from across China engaged in in-depth discussions about product technical details and clinical application scenarios, further confirming the market's recognition of the company's innovative capabilities.

-END-